75 research outputs found
Finite frequency whole mantle P wave tomography: Improvement of subducted slab images
We present a new whole mantle P wave tomographic model GAP_P4. We used two data groups; short-period data of more than 10 million picked-up onset times and long-period data of more than 20 thousand differential travel times measured by waveform cross-correlation. Finite frequency kernels were calculated at the corresponding frequency bands for both long- and short- period data. With respect to an earlier model GAP_P2, we find important improvements especially in the transition zone and uppermost lower mantle beneath the South China Sea and the southern Philippine Sea owing to broadband ocean bottom seismometers (BBOBS) deployed in the western Pacific Ocean where station coverage is poor. This new model is different from a model in which the full data set is interpreted with classical ray theory. BBOBS observations should be more useful to sharpen images of subducted slabs than expected from simple ray path coverage arguments
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049
A Survey of School Lunch Provision for Elementary School Students with Food Allergy in Seven Cities of Osaka Prefecture
Unusually deep Bonin earthquake of 30 May 2015: A precursory signal to slab penetration?
- …